ARQT
Arcutis Biotherapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -12.5% ·
share flow +2.4% ·
net new positions -14.3%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 104 | +8 | 69.45M | $1.82B | +11 | −3 |
| Q1 2026 | 99 | +1 | 69.94M | $1.65B | +6 | −6 |
| Q4 2025 | 97 | +2 | 70.50M | $2.05B | +3 | — |
| Q3 2025 | 16 | 0 | 32.55M | $613.65M | +1 | −2 |
| Q2 2025 | 14 | -2 | 28.30M | $396.73M | — | −2 |
| Q1 2025 | 13 | 0 | 11.91M | $186.25M | +1 | −1 |
| Q4 2024 | 13 | +1 | 15.11M | $210.56M | +1 | — |
| Q3 2024 | 11 | +1 | 9.54M | $88.77M | +2 | −1 |
| Q2 2024 | 10 | — | 8.25M | $76.75M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 8.53M | — | $119.63M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 2 | The Vanguard Group ✦ (passive) | 7.05M | — | $98.83M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 4.53M | +1.2% | $63.47M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.58M | +1.4% | $36.21M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | D. E. Shaw & Co. ✦ | 2.16M | +8.7% | $30.33M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 1.49M | +78.9% | $20.83M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | Millennium Management ✦ | 910.84K | +92.3% | $12.77M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 375.23K | +51.2% | $5.26M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 9 | Norges Bank ✦ (passive) | 174.82K | -74.3% | $2.45M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 150.73K | — | $2.11M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 145.49K | -53.1% | $2.04M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 84.05K | +7.8% | $1.18M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 71.68K | -52.7% | $1.00M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Wellington Management ✦ | 44.27K | -5.1% | $620,622 | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $905,681 | was 0.0% |
| Renaissance Technologies | $340,936 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 267 holders, 132.09M shares, $3.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.67K sh · $91,853
Director · 4.73K sh · $114,371
Officer · 9.99K sh · $249,986
Director · 27.05K sh · $677,095
Director · 11.15K sh · $279,028
Director · 1.07K sh · $27,912
Officer · 1.70K sh · $45,819
Director · 4.73K sh · $123,835
Officer · 6.70K sh · $174,767
Officer · 8.30K sh · $220,129
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology